Company / Accounts Receivable
TherapeuticsMD, Inc. Accounts Receivable History
FY2015-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$36.2M
FY2021
5-year range
$32.4M / $36.2M
FY2017-FY2021
Trend
+11.7%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable has increased for 4 consecutive years, from $4M in FY2017 to $36M in FY2021.
Based on SEC 10-K filings.
$36M in FY2021 with a 5-year CAGR of +51.7%.
Improved from $24M to $36M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +48.4%
- 5-Year CAGR
- +51.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- TherapeuticsMD, Inc.'s accounts receivable has grown for 4 consecutive years.
- 5-year CAGR of +51.7%, indicating consistent growth.
- In FY2021, accounts receivable increased 11.7% year-over-year.
- Lowest accounts receivable in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.77 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | $36.2M | +11.7% |
| FY2020 | $32.4M | +32.7% |
| FY2019 | $24.4M | +120.5% |
| FY2018 | $11.1M | +155.6% |
| FY2017 | $4.3M | -3.8% |
| FY2016 | $4.5M | +47.6% |
| FY2015 | $3.0M | +41.6% |
As of FY2021 · SEC 10-K · Updated Jun 28, 2026